Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | CASR | P41180 | 2/20 | 0.44 |
| ▸ | MGLL | Q99685 | 4/20 | 0.43 |
| ▸ | FAAH | O00519 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | BCL9 | O00512 | 1/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.41 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.41 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.41 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19984916 | 0.86 | CASR (0.49) | GAACASRKMT2AALDH1A1 | |
| SCHEMBL19984947 | 0.84 | CASR (0.52) | GAAATMCASRFAAHKMT2A | |
| SCHEMBL31531040 | 0.75 | MEN1 (0.62) | GAAATMFAAHKMT2AL3MBTL1 | |
| SCHEMBL10308040 | 0.75 | MEN1 (0.62) | GAAATMFAAHKMT2AL3MBTL1 | |
| SCHEMBL4430377 | 0.74 | KMT2A (0.66) | GAAATMMGLLKMT2AL3MBTL1 | |
| SCHEMBL18737584 | 0.73 | MGLL (0.46) | GAAATMMGLLKMT2AMAPT | |
| SCHEMBL30475423 | 0.73 | GAA (0.58) | GAAATMMGLLKMT2AMAPT | |
| SCHEMBL30475420 | 0.73 | GAA (0.58) | GAAATMMGLLKMT2AMAPT | |
| SCHEMBL1097040 | 0.72 | GAA (0.58) | GAAATMKMT2AMAPTALDH1A1 | |
| SCHEMBL8773960 | 0.71 | GAA (0.54) | GAAATMMGLLKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180079715-A1 | METHOD FOR PRODUCING ALKYLAMINE DERIVATIVE AND ITS PRODUCTION INTERMEDIATE OF ALKYLAMINE DERIVATIVE | AJINOMOTO CO., INC. (JP) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079715-A1 | METHOD FOR PRODUCING ALKYLAMINE DERIVATIVE AND ITS PRODUCTION INTERMEDIATE OF ALKYLAMINE DERIVATIVE | CASR, TAAR1, UTS2R | GAA 3369/4885ATM 2007/4885CASR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.